ProMIS Neurosciences P/E

What is the P/E of ProMIS Neurosciences?

The P/E of ProMIS Neurosciences, Inc. is N/A

What is the definition of P/E?

Price to earnings ratio is the ratio of a company’s stock price to the company’s earnings per share calculated over trailing twelve months.

= previous day’s close / ttm EPS

The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.

What does ProMIS Neurosciences do?

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Companies with p/e similar to ProMIS Neurosciences

Itaconix plc has P/E of N/A
Arvind has P/E of N/A
Vista Outdoor Inc has P/E of N/A
Magnite Inc has P/E of N/A
Vocera Communication Inc has P/E of N/A
Bannerman Resources has P/E of N/A
ProMIS Neurosciences has P/E of N/A
Piramal Enterprises has P/E of N/A
V2 Retail has P/E of N/A
Lithium Consolidated has P/E of N/A
Raymond has P/E of N/A
Planet Ventures has P/E of N/A
Goodman Stapled Securities has P/E of N/A